HOYOUNG HUH, M.D., PH.D. - Corporate Board Profile

GERON CORP

Filing Date	Source Excerpt
2011-03-28	Hoyoung Huh, M.D., Ph.D., has served as Executive Chairman since February 2011 and a director of the Company since May 2010. The following table provides compensation information for the year ended December 31, 2010 for each non-employee member of the Board. Huh, Hoyoung $ 3,750 53,640 129,335 186,725
2012-04-03	Hoyoung Huh, M.D., Ph.D., currently serves as Chairman of the Board, served as Executive Chairman from February 2011 to September 2011... Director Compensation Table shows total compensation of $960,139.
2013-04-05	Hoyoung Huh, M.D., Ph.D., has been the Chairman of the Board since September 2011, served as Executive Chairman from February 2011 to September 2011 and has served as a director of Geron since May 2010. ... The Board believes Dr. Huh's management and operational experience ... qualifies Dr. Huh to be nominated as a director and serve as Chairman of the Board. ... The Board has appointed Dr. Huh to join the Nominating and Corporate Governance Committee, effective as of the date of the Annual Meeting, May 22, 2013. ... The following table provides compensation information for the fiscal year ended December 31, 2012 for each non-employee member of the Board. ... Huh, Hoyoung $85,876 in fees and $28,424 in option awards totaling $114,300.
2014-04-04	Hoyoung Huh, M.D., Ph.D., has been the Chairman of the Board since September 2011, served as Executive Chairman from February 2011 to September 2011 and has served as a director of Geron since May 2010. He is Chairman of the board of directors of Cytomx Therapeutics, Inc., an emerging medical technology company. Dr. Huh also is a director of ADDEX Pharmaceuticals, a pharmaceutical discovery and development company, and AntriaBio, Inc., a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. From February 2008 to December 2011, Dr. Huh was Chairman of the board of directors of BiPar Sciences, Inc., a wholly-owned subsidiary of Sanofi-Aventis, a global pharmaceutical company developing treatments in cardiology, oncology, central nervous system disorders, metabolic diseases, ophthalmology and vaccines since the April 2009 merger of BiPar and Sanofi-Aventis, and served as BiPar's President and Chief Executive Officer from February 2008 to December 2009. Additionally, Dr. Huh serves on the boards of directors of several privately-held companies. Dr. Huh served on the board of directors of Facet Biotech (a wholly-owned subsidiary of Abbott, a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics) from September 2009 to April 2010. From February 2008 to May 2009, he was a member of the board of directors at Nektar Therapeutics, a clinical-stage biopharmaceutical company developing small molecule drugs, peptides and other biologic drug candidates as treatments for oncology, pain, anti-infectives, anti-virals and immunology. From March 2005 to February 2008, Dr. Huh held positions as Nektar's Chief Operating Officer and Senior Vice President of Business Development and Marketing where he was responsible for the company's worldwide business development, marketing and manufacturing and led Nektar's PEGylation business. Prior to Nektar, Dr. Huh was a partner at McKinsey & Company, a global management consulting firm, where he was in the biotechnology and biopharmaceutical sectors. Prior to McKinsey, he held positions as a physician and researcher at Cornell University Medical College and Sloan-Kettering Cancer Center. Dr. Huh holds an A.B. in biochemistry from Dartmouth College and an M.D. and Ph.D. in genetics and cell biology from Cornell University Medical College and Sloan-Kettering Institute. The Board believes Dr. Huh's management and operational experience as President and Chief Executive Officer of BiPar Sciences and Chief Operating Officer of Nektar Therapeutics, his significant expertise with implementing strategic and line management initiatives from McKinsey and his knowledge of biotechnology and pharmaceutical collaborations, qualifies Dr. Huh to serve as a director and serve as Chairman of the Board.
2015-04-03	Hoyoung Huh, M.D., Ph.D., has been the Chairman of the Board since September 2011. Compensation Table shows total compensation of $126,450.
2016-04-01	Hoyoung Huh, M.D., Ph.D., has been the Chairman of the Board since September 2011, served as our interim Executive Chairman from February 2011 to September 2011, and has served as a director of Geron since May 2010. ... The Board has an independent Chair, Dr. Huh, who has authority, among other things, to call and preside over Board meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to the Board. ... The following table provides compensation information for the fiscal year ended December 31, 2015 ("fiscal 2015"), for each non-employee member of the Board who served in such capacity during fiscal 2015. ... Huh, Hoyoung $ 77,500 $ 96,229 $ 173,729
2017-03-24	Hoyoung Huh, M.D., Ph.D. 47 Yes M 2 Chairman of the Board Independent Director ... Geron Committee Memberships - Nominating and Corporate Governance Committee ... Director Compensation Table ... Huh, Hoyoung $77,500 $97,760 $175,260
2018-03-30	Hoyoung Huh, M.D., Ph.D. 48 Yes M 2 Chairman of the Board Independent Director